Literature DB >> 18589844

The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis.

Adam N Williams1, Katharine M Woessner.   

Abstract

Aspirin-exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs). For patients who have inadequately controlled rhinosinusitis and/or asthma despite treatment with topical corticosteroids and leukotriene-modifying drugs, aspirin desensitization is an important therapeutic option. This review examines the evidence supporting the effectiveness of aspirin desensitization for the treatment of chronic rhinosinusitis in patients with AERD. Practical aspects of conducting safe aspirin desensitization procedures and optimizing therapeutic benefits are also reviewed. When conducted in accordance with current guidelines, aspirin desensitization is a safe procedure that allows patients with AERD who have an indication for aspirin or other NSAIDs to safely ingest these medications. There is now strong evidence that aspirin desensitization and daily aspirin therapy is effective for treatment of the chronic inflammatory disease of the upper airway and lower airways in AERD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18589844     DOI: 10.1007/s11882-008-0041-7

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.919


  39 in total

1.  Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics.

Authors:  M Sanak; B D Levy; C B Clish; N Chiang; K Gronert; L Mastalerz; C N Serhan; A Szczeklik
Journal:  Eur Respir J       Date:  2000-07       Impact factor: 16.671

Review 2.  Selection of patients for aspirin desensitization treatment.

Authors:  Donald D Stevenson; Ronald A Simon
Journal:  J Allergy Clin Immunol       Date:  2006-07-24       Impact factor: 10.793

3.  Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease.

Authors:  Jennifer Y Lee; Ronald A Simon; Donald D Stevenson
Journal:  J Allergy Clin Immunol       Date:  2006-11-13       Impact factor: 10.793

4.  Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma.

Authors:  L Mastalerz; M Milewski; M Duplaga; E Nizankowska; A Szczeklik
Journal:  Allergy       Date:  1997-09       Impact factor: 13.146

5.  Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes.

Authors:  D D Stevenson; M A Hankammer; D A Mathison; S C Christiansen; R A Simon
Journal:  J Allergy Clin Immunol       Date:  1996-10       Impact factor: 10.793

6.  Aspirin intolerance in asthma. Detection by oral challenge.

Authors:  J R McDonald; D A Mathison; D D Stevenson
Journal:  J Allergy Clin Immunol       Date:  1972-10       Impact factor: 10.793

7.  The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions.

Authors:  M P Berges-Gimeno; R A Simon; D D Stevenson
Journal:  Clin Exp Allergy       Date:  2002-10       Impact factor: 5.018

8.  Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease.

Authors:  M Pilar Berges-Gimeno; Ronald A Simon; Donald D Stevenson
Journal:  Ann Allergy Asthma Immunol       Date:  2003-03       Impact factor: 6.347

9.  Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges.

Authors:  D D Stevenson; R A Simon; D A Mathison
Journal:  J Allergy Clin Immunol       Date:  1980-07       Impact factor: 10.793

10.  Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma.

Authors:  N Ogata; Y Darby; G Scadding
Journal:  J Laryngol Otol       Date:  2007-08-15       Impact factor: 1.469

View more
  5 in total

Review 1.  Rhinosinusitis and comorbidities.

Authors:  Matthew W Ryan; Edward G Brooks
Journal:  Curr Allergy Asthma Rep       Date:  2010-05       Impact factor: 4.806

2.  [Aspirin desensitization: therapy options in patients with aspirin-exacerbated respiratory disease].

Authors:  R Weber; A Trautmann; W Randerath; W Heppt; W Hosemann
Journal:  HNO       Date:  2012-04       Impact factor: 1.284

3.  Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology.

Authors:  Cezmi A Akdis; Claus Bachert; Cemal Cingi; Mark S Dykewicz; Peter W Hellings; Robert M Naclerio; Robert P Schleimer; Dennis Ledford
Journal:  J Allergy Clin Immunol       Date:  2013-04-12       Impact factor: 10.793

4.  NSAIDs Naproxen, Ibuprofen, Salicylate, and Aspirin Inhibit TRPM7 Channels by Cytosolic Acidification.

Authors:  Rikki Chokshi; Orville Bennett; Tetyana Zhelay; J Ashot Kozak
Journal:  Front Physiol       Date:  2021-10-18       Impact factor: 4.566

5.  Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease.

Authors:  Negar Mortazavi; Hossein Esmaeilzadeh; Mohammad Abbasinazari; Delara Babaie; Soheila Alyasin; Hesamodin Nabavizadeh; Elmira Esmailzadeh
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.